across the US, UK, and EU regions. This article provides an end-to-end process guide covering clinical trial site feasibility from the initial concept phase through to study close-out. It is designed for clinical operations, regulatory affairs, and medical affairs professionals who require a detailed understanding of how to assess, select, and manage clinical trial sites in compliance with regulatory expectations such as those from the FDA, EMA, and MHRA. The article also integrates key concepts from ICH guidelines and global best practices to ensure scientific validity, patient safety, and regulatory compliance throughout the clinical trial lifecycle.

Context and Core Definitions for Clinical Trial Site Feasibility

Understanding clinical trial site feasibility requires familiarity with several foundational terms and concepts that inform site selection and study planning. Clinical trial site feasibility refers to the systematic evaluation of potential investigational sites to determine their capability, suitability, and readiness to conduct a clinical trial according to protocol requirements and regulatory standards. This evaluation includes assessing patient population availability, site infrastructure, staff expertise, regulatory environment, and logistical considerations.

A feasibility study clinical trial is often conducted as a preliminary step to assess these factors before full trial initiation. It may involve deploying a feasibility questionnaire clinical trials tool, which collects standardized data from sites on their experience, recruitment potential, and operational capacity. The outcome of this process informs site selection decisions and resource allocation.

In the context of the clinical trial lifecycle, site feasibility is typically performed during the protocol development and planning phase, bridging the conceptual design and operational execution. Proper feasibility assessment ensures alignment with regulatory expectations, reduces risks related to recruitment delays or protocol deviations, and supports data integrity and patient safety. For global trials, such as those similar to the CodeBreak 100 trial—a notable oncology study with multinational sites—feasibility assessments must consider regional regulatory nuances and site-specific capabilities.

Regulatory and GCP Expectations in US, EU, and UK

Regulatory authorities in the US, EU, and UK emphasize rigorous site feasibility assessments as part of Good Clinical Practice (GCP) compliance. The FDA’s 21 CFR Part 312 outlines sponsor responsibilities to ensure that clinical investigators and sites are qualified and capable of conducting the trial. Similarly, the EU Clinical Trials Regulation (EU-CTR 536/2014) mandates that sponsors verify sites’ suitability, including infrastructure, staffing, and experience, before trial initiation.

The UK’s MHRA aligns with ICH E6(R3) GCP guidelines, which require sponsors to conduct thorough feasibility assessments to mitigate risks related to site selection. ICH E8(R1) and E9(R1) further reinforce the importance of site feasibility in ensuring trial quality and data reliability. These guidelines specify that feasibility evaluations should be documented, reproducible, and include consideration of patient recruitment projections, site workload, and regulatory compliance history.

Operationalizing these regulatory requirements involves sponsors and CROs collaborating to design feasibility questionnaires and tools, conduct site visits, and review historical performance data. Sites must demonstrate adequate facilities, qualified personnel, and experience with the investigational product and protocol design. Failure to comply with these expectations can lead to regulatory findings during inspections and jeopardize trial approval or data acceptance.

Practical Design and Operational Considerations for Clinical Trial Site Feasibility

Implementing clinical trial site feasibility effectively requires a structured, stepwise approach. Below is a detailed operational framework to guide clinical trial teams:

1. Define feasibility objectives: Clarify what parameters are critical for the trial’s success, including recruitment targets, specialized procedures, and regulatory requirements.
2. Develop or customize a feasibility questionnaire clinical trials tool: Include questions on patient demographics, prior trial experience, staff qualifications, site infrastructure, and regulatory compliance history.
3. Identify potential sites: Use databases, prior trial records, and investigator networks to compile a list of candidate sites across the US, UK, and EU.
4. Distribute feasibility questionnaires and collect responses: Ensure timely follow-up and clarification to maximize response rates and data quality.
5. Analyze feasibility data: Evaluate recruitment potential, operational capacity, and risk factors quantitatively and qualitatively.
6. Conduct site qualification visits: Verify questionnaire data through on-site assessments focusing on facilities, equipment, and staff training.
7. Select sites based on feasibility outcomes: Prioritize sites with strong recruitment potential, compliance history, and operational readiness.
8. Integrate feasibility findings into protocol and operational plans: Adjust recruitment timelines, resource allocation, and monitoring strategies accordingly.

Throughout this process, clear role delineation is essential. Sponsors oversee feasibility strategy and regulatory compliance; CROs often manage questionnaire distribution, data collection, and site assessments; principal investigators (PIs) and site staff provide accurate data and demonstrate capability. For example, in the CodeBreak 100 trial, detailed feasibility assessments enabled identification of high-performing oncology centers across multiple regions, facilitating timely enrollment and regulatory submissions.

Common Pitfalls, Inspection Findings, and How to Avoid Them

Regulatory inspections frequently identify deficiencies related to clinical trial site feasibility. Common pitfalls include:

• Incomplete or inaccurate feasibility data: Sites may overestimate recruitment potential or underreport operational limitations, leading to unrealistic enrollment projections.
• Lack of documented feasibility assessments: Failure to maintain records of feasibility questionnaires, site visits, and decision rationale undermines compliance.
• Insufficient consideration of regulatory environment: Ignoring regional differences in regulatory requirements or site capabilities can cause delays or non-compliance.
• Inadequate training of site staff: Sites selected without verifying staff qualifications or training history risk protocol deviations and data quality issues.

These issues impact data integrity, patient safety, and trial timelines. To mitigate risks, teams should implement robust SOPs for feasibility assessments, ensure comprehensive training on feasibility tools, and conduct periodic audits of site performance against feasibility predictions. Metrics such as recruitment rates versus projections and protocol adherence rates should be monitored continuously to identify emerging issues early.

US vs EU vs UK Nuances and Real-World Case Examples

While the core principles of clinical trial site feasibility are consistent across the US, EU, and UK, there are notable regional differences:

• Regulatory submission processes: The EU’s centralized EU Clinical Trials Information System (CTIS) requires sponsors to submit feasibility data as part of the initial application, whereas the FDA’s IND process emphasizes site qualification documentation during sponsor inspections.
• Data protection and privacy: The EU’s GDPR imposes stricter controls on patient data collected during feasibility assessments compared to the US HIPAA framework, requiring tailored consent and data handling procedures.
• Site qualification timelines: The MHRA in the UK often expects earlier site readiness confirmation due to accelerated trial authorization pathways post-Brexit.

Case Example 1: In a multinational oncology trial modeled after the CodeBreak 100 trial, a sponsor encountered delayed recruitment in EU sites due to underestimation of patient availability during feasibility. A subsequent root cause analysis revealed incomplete feasibility questionnaires and lack of site visits. Remediation included enhanced questionnaire design and mandatory site qualification visits, which improved recruitment rates.

Case Example 2: A US-based trial experienced FDA inspection findings related to undocumented feasibility assessments. The sponsor responded by implementing a centralized electronic feasibility tracking system, integrating documentation with site initiation records, which facilitated compliance and inspection readiness.

Multinational teams should harmonize feasibility procedures by adopting common tools, aligning data collection standards, and incorporating region-specific regulatory requirements early in the planning phase to optimize site selection and trial conduct.

Implementation Roadmap and Best-Practice Checklist

To operationalize clinical trial site feasibility effectively, clinical trial teams should follow this implementation roadmap:

1. Establish feasibility objectives and criteria: Define recruitment targets, site capabilities, and regulatory considerations specific to trial design and geography.
2. Develop standardized feasibility questionnaires: Include core questions and region-specific items to capture comprehensive site data.
3. Identify and engage potential sites: Utilize databases, investigator networks, and prior trial performance data.
4. Distribute questionnaires and collect data: Ensure clear communication and deadlines for responses.
5. Perform data analysis and risk assessment: Evaluate feasibility data against trial requirements and identify potential risks.
6. Conduct site qualification visits: Verify infrastructure, staff qualifications, and regulatory compliance.
7. Select sites and document rationale: Maintain detailed records to support regulatory inspections.
8. Integrate feasibility outcomes into trial planning: Adjust recruitment strategies, monitoring plans, and resource allocation.
9. Implement ongoing feasibility monitoring: Track recruitment performance and site adherence throughout the trial.

Below is a best-practice checklist to incorporate into SOPs and training:

• Use validated feasibility questionnaires tailored to trial and regional needs.
• Document all feasibility assessments and site qualification activities comprehensively.
• Train clinical operations and site staff on feasibility processes and expectations.
• Incorporate regulatory requirements from FDA, EMA, and MHRA into feasibility workflows.
• Establish metrics to monitor recruitment versus feasibility projections continuously.
• Ensure data privacy compliance, especially under GDPR for EU sites.
• Schedule periodic feasibility re-assessments for long-duration trials.
• Maintain clear communication channels between sponsors, CROs, and sites.

Comparison of Clinical Trial Site Feasibility Regulatory and Operational Nuances: US, EU, and UK

Aspect	US (FDA)	EU (EMA/EU-CTR)	UK (MHRA)
Regulatory Framework	21 CFR Part 312, ICH E6(R3)	EU Clinical Trials Regulation (536/2014), ICH E6(R3)	MHRA GCP Guidance, ICH E6(R3)
Feasibility Documentation	Required for sponsor inspections; no formal submission	Part of initial CTIS submission and ongoing oversight	Emphasis on early site readiness confirmation
Data Privacy Considerations	HIPAA applies; variable by state	GDPR strict controls on patient data	GDPR aligned post-Brexit; UK Data Protection Act
Site Qualification Visits	Recommended; often required for high-risk trials	Strongly recommended; may be inspected	Expected as part of site readiness assessment
Recruitment Projections	Critical for IND submissions and monitoring	Included in protocol and CTIS application	Monitored closely due to accelerated timelines

Key Takeaways for Clinical Trial Teams

• Clinical trial site feasibility is essential to align site capabilities with protocol requirements and regulatory expectations, reducing risks to trial integrity and timelines.
• Regulatory frameworks from FDA, EMA, and MHRA mandate documented and thorough feasibility assessments to ensure qualified site selection and compliance.
• Implementing standardized feasibility questionnaires, site visits, and ongoing monitoring supports data quality and patient safety throughout the trial lifecycle.
• Understanding and addressing regional differences in regulatory submissions, data privacy, and site readiness enhances multinational trial harmonization and operational efficiency.